Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Item 9 Labs (INLB) Liabilities and Shareholders Equity (2016 - 2023)

Item 9 Labs' Liabilities and Shareholders Equity history spans 13 years, with the latest figure at $112.0 million for Q2 2023.

  • For Q2 2023, Liabilities and Shareholders Equity fell 7.06% year-over-year to $112.0 million; the TTM value through Jun 2023 reached $451.6 million, down 4.98%, while the annual FY2022 figure was $110.8 million, 5.18% down from the prior year.
  • Liabilities and Shareholders Equity reached $112.0 million in Q2 2023 per INLB's latest filing, down from $114.1 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $153.1 million in Q1 2021 to a low of $14.5 million in Q3 2019.
  • Average Liabilities and Shareholders Equity over 5 years is $84.2 million, with a median of $113.1 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 572.02% in 2021, then decreased 21.07% in 2022.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $14.6 million in 2019, then skyrocketed by 77.44% to $26.0 million in 2020, then surged by 350.37% to $117.0 million in 2021, then dropped by 2.01% to $114.7 million in 2022, then fell by 2.32% to $112.0 million in 2023.
  • Per Business Quant, the three most recent readings for INLB's Liabilities and Shareholders Equity are $112.0 million (Q2 2023), $114.1 million (Q1 2023), and $114.7 million (Q4 2022).